Dogwood Therapeutics, Inc. (Nasdaq: DWTX) reported financial results for the first quarter ended March 31, 2026, emphasizing significant advancements in its pipeline, including the Phase 2b study of Halneuron® for chemotherapy-induced neuropathic pain (CINP) and FDA clearance for SP16 to enter Phase 1b development. The company's cash position of $13.2 million is expected to fund operations into the fourth quarter of 2026.
Greg Duncan, CEO of Dogwood Therapeutics, stated, "Dogwood is off to a strong operational start to 2026 driven by significant pipeline progress for both Halneuron®, with Phase 2b data anticipated this fall, and SP16, which received FDA clearance to progress into Phase 1b development this quarter. Furthermore, we executed a global development license for our legacy combination antiviral assets."
The company has enrolled 164 patients in its Halneuron® Phase 2b CINP study, with top-line results expected in fall 2026. Halneuron® is a non-opioid, NaV 1.7 inhibitor that has received fast track designation from the FDA for CINP. Separately, SP16, an LRP1 agonist for chemotherapy-induced pain and peripheral neuropathy (CIPPN), received IND approval and will begin enrolling patients in mid-2026. The Phase 1b trial is fully funded by the National Cancer Institute and will be conducted at the University of Virginia.
Financially, Dogwood reported research and development expenses of $2.7 million for Q1 2026, up from $2.4 million in Q1 2025, driven by increased drug development costs for Halneuron® and higher personnel costs. General and administrative expenses rose to $2.4 million from $2.0 million, primarily due to higher salaries. Net loss attributable to common stockholders was $5.0 million, or $0.15 per share, compared to a net loss of $12.2 million, or $8.45 per share, in the prior-year period.
Dogwood Therapeutics focuses on developing first-in-class non-opioid medicines for pain and neuropathy. Its pipeline includes Halneuron® and SP16 IV. The company's largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., listed on the Hong Kong Stock Exchange (stock code: 0775). For more information, visit www.dwtx.com.
The company also noted that any payments from development and commercialization partnerships that qualify as upfront or milestone payments will be delivered to the rights agent for holders of contingent value rights issued in October 2024.
